Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Subcommittee to Study “Notification System” for Access to Unapproved Drugs
November 17, 2011
- PM Noda Says “Japan Will Not Lose” Public Health Insurance System in TPP
November 16, 2011
- Health Minister Komiyama Says “Government Position Recognized” in Iressa Case
November 16, 2011
- DPJ’s Medical and Nursing Care WT Discuss Promotion of Generic Drugs
November 16, 2011
- High Court Turns Down Iressa Compensation Appeal
November 16, 2011
- 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
- Mr Sawai of JGA Opposes Reduction in NHI Prices of First Generics
November 16, 2011
- PAFSC Committee Recommends Classification of Isoconazole as Class 1 OTC Drug
November 15, 2011
- Merck Withdraws MAA for Sitagliptin, Pioglitazone Combination
November 15, 2011
- Former Health Minister Masuzoe Raises Drug Re-Pricing Issues Over TPP
November 14, 2011
- 2007’s “Emergency Proposal” for Distribution Reform Needs Review: Health Ministry Councilor Mr Takeda
November 11, 2011
- Discontinuation of Vaccination Following Death due to Unknown Cause Cannot Be Considered: David Salisbury, UK Director for Vaccines and Immunization
November 11, 2011
- MHLW Calls for Package Insert Revision for Bisphosphonates
November 11, 2011
- PMDA Draws Up "Global Vision" to Establish World Class Position
November 10, 2011
- MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
- Mr Kobayashi of Kyokai Kenpo Proposes Measures to Promote GE Drug Use
November 10, 2011
- Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
- Promote “Category-based” Negotiations Instead of Package Deals: Mr Hasegawa
November 10, 2011
- PAFSC Committee Approves Extension of Reexamination Period for DSP’s Lonasen
November 9, 2011
- MHLW Announces Add’l Indications Eligible for Applications Based on Info in Public Domain
November 9, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…